当前位置:产品中心 > 抗体 > Biosimilar抗体 > TAA > Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]
Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]
基本信息

产品编号:GM-87824AB

产品名称:Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]

目录价:询价


产品配图.jpg


规格货号

GM-87824AB-100       100μg

GM-87824AB-1mg      1mg


产品简介

Expression System

CHO

Purity

> 95% as determined by SDS-PAGE

Aggregation

< 5% as determined by SEC-HPLC

Drug-to-Antibody Ratio (DAR)

8.0

Endotoxin

<1EU/mg

Sterility

0.22 μm Filtered

Target

CD227

Clone

DS-3939

Alternative Names

ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3, EMA, H23AG, KL-6, MAM6, MCD, MCKD, MCKD1, MUC-1, MUC-1/SEC, MUC-1/X/ZD, PEM, PEMT, PUM

Source/Isotype

Monoclonal Human IgG1, κ

Application

Positive control of Cytotoxicity Assay

Description

DS-3939 is an antibody-drug conjugate (ADC) candidate drug developed for targeted cancer therapy. It typically consists of a monoclonal antibody that specifically recognizes tumor-associated antigens, chemically linked to a cytotoxic payload. This type of drug aims to enhance antitumor activity and selectivity by precisely targeting tumor cells via the antibody, thereby reducing damage to normal cells.

Formulation

10 mM NaAc-HAc, pH5.0


数据展示

image.png


image.png

image.png


当前位置:产品中心 > 抗体 > Biosimilar抗体 > Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]

Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]
基本信息

产品编号:GM-87824AB

产品名称:Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]

目录价:询价


产品配图.jpg


规格货号

GM-87824AB-100       100μg

GM-87824AB-1mg      1mg


产品简介

Expression System

CHO

Purity

> 95% as determined by SDS-PAGE

Aggregation

< 5% as determined by SEC-HPLC

Drug-to-Antibody Ratio (DAR)

8.0

Endotoxin

<1EU/mg

Sterility

0.22 μm Filtered

Target

CD227

Clone

DS-3939

Alternative Names

ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3, EMA, H23AG, KL-6, MAM6, MCD, MCKD, MCKD1, MUC-1, MUC-1/SEC, MUC-1/X/ZD, PEM, PEMT, PUM

Source/Isotype

Monoclonal Human IgG1, κ

Application

Positive control of Cytotoxicity Assay

Description

DS-3939 is an antibody-drug conjugate (ADC) candidate drug developed for targeted cancer therapy. It typically consists of a monoclonal antibody that specifically recognizes tumor-associated antigens, chemically linked to a cytotoxic payload. This type of drug aims to enhance antitumor activity and selectivity by precisely targeting tumor cells via the antibody, thereby reducing damage to normal cells.

Formulation

10 mM NaAc-HAc, pH5.0


数据展示

image.png


image.png

image.png


Tel: 400-627-9288
留言咨询
重置
提交
客服
微信
电话
留言
留言咨询
重置
提交